Jazz Pharmaceuticals in its $935 million all-cash acquisition of Chimerix
On March 4, 2025, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Chimerix, Inc. (NASDAQ: CMRX), a biopharmaceutical company focused on the discovery, development and commercialization of medicines for the treatment of cancer and other deadly diseases, entered into a definitive agreement pursuant to which Jazz will acquire Chimerix in an all-cash transaction for $8.55 per share, representing an equity value of approximately $935 million.
Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Jazz.